CORRELATION OF SERUM TRIGLYCERIDES WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS PATIENTS
DOI:
https://doi.org/10.61841/d0h4wf41Keywords:
Triglycerides, Type 2 Diabetes Mellitus, Hba1c, Lipid Profile, Cardiovascular RiskAbstract
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, hyperglycaemia, and associated lipid abnormalities, which significantly increase the risk of cardiovascular diseases. Among these abnormalities, elevated serum triglyceride levels play a crucial role in the development of metabolic complications. The present study aimed to evaluate the correlation between serum triglyceride levels and newly diagnosed T2DM patients. This prospective longitudinal study was conducted over a period of six months and included a total of 200 newly diagnosed T2DM patients aged between 35–60 years. Blood samples were collected under standard conditions and analysed for fasting blood glucose (FBS), postprandial blood glucose (PPBS), glycated hemoglobin (HbA1c), and serum triglyceride levels using semi-automated biochemical analyzers. Statistical analysis was performed to assess the relationship between triglyceride levels and glycaemic parameters. The results demonstrated that approximately 43% of the study population exhibited elevated serum triglyceride levels. A positive correlation was observed between triglyceride levels and glycemic indicators such as HbA1c and blood glucose levels, suggesting that poor glycemic control is associated with dyslipidemia. Both male and female patients showed similar trends, indicating that the association is independent of gender.The findings of this study highlight that elevated triglyceride levels are common in newly diagnosed T2DM patients and may serve as an early indicator of increased cardiovascular risk. Therefore, routine assessment of lipid profiles, particularly triglycerides, should be incorporated into the initial evaluation and management of diabetic patients.
References
Causes of Diabetes. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). June 2014. Archived from the original on 2 February 2016. Retrieved 10 February 2016.
Diabetes Fact Sheet No. 312. World Health Organization (WHO). August 2011. Archived from the original on 26 August 2013. Retrieved 2012.
Diagnosis of Diabetes and Prediabetes. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). June 2014. Archived from the original on 6 March 2016. Retrieved 10 February 2016.
Pasquel, F.J., & Umpierrez, G.E. (2015). A historic review of the clinical presentation, diagnosis, and treatment of diabetic ketoacidosis. Diabetes Care.
Fasanmade, O.A., Odeniyi, I.A., & Ogbera, A.O. (2015). Diabetic ketoacidosis: Diagnosis and management. African Journal of Medicine and Medical Sciences, 37(2), 99–105. PMID: 18939392.
Ganguly, S., Tan, H.C., Lee, P.C., & Tham, K.W. (2015). Metabolic bariatric surgery and type 2 diabetes mellitus: An endocrinologist’s perspective. Journal of Biomedical Research.
Rathee, M., & Prachi, J. (2019). Ageusia. In StatPearls. StatPearls Publishing.
Pedersen, H.K., Gudmundsdottir, V., Nielsen, H.B., Hyotylainen, T., Nielsen, T., Jensen, B.A., et al. (2016). Human gut microbes impact host serum metabolome and insulin sensitivity.
Reynolds, A., Mann, J., Cummings, J., Winter, N., Mete, E., & Te Morenga, L. (2019). Carbohydrate quality and human health: A series of systematic reviews and meta-analyses.
Emdin, C.A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015). Blood pressure lowering in type 2 diabetes: A systematic review and meta-analysis.
Shang, V.O., Boateng, K.A., & Mensah, F.O. (2015). Prevalence of metabolic syndrome in type 2 diabetes mellitus patients. International Journal of Applied and Basic Medical Research.
Zaidi, S.M.H., Ghafoor, A., & Randhawa, F.A. (2015). HbA1c as an indirect marker of hypertriglyceridemia in type 2 diabetes mellitus. Journal of Ayub Medical College Abbottabad.
Jemima, P.G. (2015). Prevalence of hypertriglyceridemia among newly detected type 2 diabetes patients in Coimbatore.
Qaseem, A., Wilt, T.J., Kansagara, D., Horwitch, C., Barry, M.J., & Forciea, M.A. (2016). Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: A guidance statement update from the American College of Physicians. Annals of Internal Medicine.
Makam, A.N., & Nguyen, O.K. (2017). An evidence-based medicine approach to antihyperglycemic therapy in diabetes mellitus to overcome overtreatment.
Simpson, T.C., Weldon, J.C., Worthington, H.V., Needleman, I., Wild, S.H., Moles, D.R., Stevenson, B., Furness, S., & Iheozor-Ejiofor, Z. (2015). Treatment of periodontal disease for glycemic control in people with diabetes mellitus.
Smith, A.D., Crippa, A., Woodcock, J., & Brage, S. (2016). Physical activity and incident type 2 diabetes mellitus: A systematic review and dose-response meta-analysis of prospective cohort studies.
Feinman, R.D., Pogozelski, W.K., Astrup, A., Bernstein, R.K., Fine, E.J., Westman, E.C., et al. (2015). Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base.
Jovanovski, E., Khayyat, R., Zurbau, A., Komishon, A., Mazhar, N., Sievenpiper, J.L., et al. (2019). Should viscous fiber supplements be considered in diabetes control? Results from a systematic review and meta-analysis of randomized controlled trials.
Muley, A., Fernandez, R., Ellwood, L., Muley, P., & Shah, M. (2021). Effect of tree nuts on glycemic outcomes in adults with type 2 diabetes mellitus: A systematic review.
Essential Fatty Acids. Micronutrient Information Center, Oregon State University, Corvallis, OR. Retrieved 24 May 2017.
Schmidt, M.I., Duncan, B.B., Bang, H., Pankow, J.S., Ballantyne, C.M., Golden, S.H., Folsom, A.R., & Chambless, L.E. (2015). Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities Study. Diabetes Care.
World Health Organization. (2017). World Health Statistics: Monitoring Health for the Sustainable Development Goals (SDGs). Geneva: WHO.
Cavero-Redondo, I., Peleteiro, B., Alvarez-Bueno, C., Rodriguez-Artalejo, F., & Martinez-Vizcaino, V. (2017). Glycated hemoglobin A1c as a risk factor for cardiovascular outcomes and all-cause mortality in diabetic and nondiabetic populations: A systematic review and meta-analysis.
Sone, H., Nakagami, T., Nishimura, R., Tajima, N., & MEGA Study Group. (2016). Comparison of lipid parameters to predict cardiovascular events in Japanese mild-to-moderate hypercholesterolemic patients with and without type 2 diabetes: Sub-analysis of the MEGA study. Diabetes Research and Clinical Practice.
Ganda, O.P., Bhatt, D.L., Mason, R.P., Miller, M., & Boden, W.E. (2018). Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. Journal of the American College of Cardiology, 72(3), 330–343.
Nichols, G.A., Philip, S., Reynolds, K., Granowitz, C.B., & Fazio, S. (2019). Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol.
Tani, S., Yagi, T., Atsumi, W., Kawauchi, K., Matsuo, R., & Hirayama, A. (2017). Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: A cross-sectional study.
Han, T., Cheng, Y., Tian, S., Wang, L., Liang, X., Duan, W., Na, L., & Sun, C. (2016). Changes in triglycerides and high-density lipoprotein cholesterol may precede peripheral insulin resistance, with 2-hour insulin partially mediating this unidirectional relationship: A prospective cohort study.
Bowman, L., Mafham, M., Wallendszus, K., Stevens, W., Buck, G., Barton, J., Murphy, K., Aung, T., Haynes, R., Cox, J., et al. (2018). Effects of n-3 fatty acid supplements in diabetes mellitus.
Aung, T., Halsey, J., Kromhout, D., Gerstein, H.C., Marchioli, R., Tavazzi, L., Geleijnse, J.M., Rauch, B., Ness, A., Galan, P., et al. (2018). Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: Meta-analysis of 10 trials involving 77,917 individuals. JAMA Cardiology.
Bhatt, D.L., Steg, P.G., Miller, M., Brinton, E.A., Jacobson, T.A., Ketchum, S.B., Doyle, R.T. Jr., Juliano, R.A., Jiao, L., Granowitz, C., et al. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
